Navigation Links
A sip of resveratrol and a full p53: Ingredients for a successful cell death

Rio de Janeiro, Brazil- Resveratrol is a naturally occurring dietary compound found in grapes, berries, and peanuts. This polyphenol protects plants against pathogens such as bacteria and fungi by inducing cell death in invading organisms. The compound was discovered in red wine in 1939 but by large did not attract the attention of the scientific community. More recently, pre-clinical studies have revealed the many beneficial properties of resveratrol. These include antidiabetic, cardioprotective, and chemopreventive effects. The latter has been associated to resveratrol antioxidant and anti-inflammatory proprieties.

A number of studies show that resveratrol induces cell death in different types of cancers, both in humans and animal models. However, the potential anti-tumor effect of resveratrol is still little understood as the compound seems to induce cell death in a number of cancer cells whereas in others no effect is observed, even when massive doses of resveratrol are used. A phase I study on the pharmacokinetic properties of resveratrol as a potential cancer chemopreventive agent has concluded that consumption of high levels of resveratrol would be insufficient to provide the amounts of resveratrol needed to elicit its chemopreventive proprieties. Nevertheless, a few ongoing clinical trials investigate the effects of resveratrol on a number of diseases, including colon cancer.

More recently, the anti-tumor functions of resveratrol have been associated to p53, a protein responsible for suppressing tumor development in the body. p53 is one of the main blockers of the cell cycle, leading cells to the death row. A faulty p53 is unable to suppress cell growth, which ultimately results in tumor development. Indeed, studies have shown that p53 is either defective or simply absent in most cancers.

To investigate whether resveratrol anti-tumor effects, as observed in some cancer cell lines, depend on the status of the cell's p53 gene, a group led by Dr Jerson L. Silva at the Universidade Federal do Rio de Janeiro, Brazil, tested the effects of resveratrol in H1299, a human non-small lung carcinoma cell line carrying only a partial fragment of the p53 gene and compared the results with MCF-7, A549, and H460, which are cancer cell lines carrying normal copies of p53. The study shows that although resveratrol affects the viability of all cancer cell lines, MCF-7, A549, and H460 are more sensitive to the effects of resveratrol than H1299. While MCF-7 cell lines die after exposure to resveratrol, H1299 remains resistant. Additional findings indicate that the toxic effect of resveratrol on MCF-7, A549, and H460 cell lines is mediated by p53.

The research group then went one step further and asked what would happen if a normal copy of p53 is added to the previously p53-defective H1299 cancer cell line. The results, published this week in PLOS ONE, show that introduction of a normal copy of p53 in H1299 turns the cell line sensitive to the anti-tumor effects of resveratrol, similarly to that observed in other cancer cell lines (MCF-7, A549, and H460). "Our findings may have potential applications in cancer cell lines that are under p53 control," says Dr Danielly Ferraz da Costa, the first author of the study. "Also, the introduction of the p53 gene in p53-defective tumors, followed by resveratrol treatment, may represent a novel and promising therapeutic approach in our fight against cancer," says the young author.


Contact: Jerson Lima Silva
Publicase Comunicao Cientfica

Related biology news :

1. Resveratrol may be a natural exercise performance enhancer: U of A medical research
2. The effect of catch-up growth by various diets and resveratrol intervention on bone status
3. New oil spill dispersant made from ingredients in peanut butter, chocolate, ice cream
4. Chinese scientists successfully crack the genome of diploid cotton
5. First paternity study of southern right whales finds local fathers most successful
6. Successful stem cell differentiation requires DNA compaction, study finds
7. Chronic kidney disease increases risk of death at all ages
8. Mount Sinai researchers solve mystery surrounding the death of two sisters nearly 50 years ago
9. Allergies? Your sneeze is a biological response to the noses blue screen of death
10. Sickle cell trait can cause sudden cardiac death in black athletes: Why is this controversial?
11. Lace plants explain programmed cell death
Post Your Comments:
(Date:11/18/2015)... 2015 --> ... market report titled  Gesture Recognition Market - Global Industry ... 2021. According to the report, the global gesture recognition market was valued ... reach US$29.1 bn by 2021, at a CAGR of ... America dominated the global gesture recognition market ...
(Date:11/16/2015)... 2015  Synaptics Inc. (NASDAQ: SYNA ), ... announced expansion of its TDDI product portfolio with ... and display driver integration (TDDI) solutions designed to ... TDDI products add to the previously-announced TD4300 ... resolution), and TD4322 (FHD resolution) solutions. All four ...
(Date:11/10/2015)... LONDON , Nov. 10, 2015 /PRNewswire/ ... segmented on the basis of product, type, ... segments included in this report are consumables, ... this report are safety biomarkers, efficacy biomarkers, ... in this report are diagnostics development, drug ...
Breaking Biology News(10 mins):
(Date:11/30/2015)... ... November 30, 2015 , ... Global Stem Cells Group ... professionals from Central America and abroad for the first Iberoamerican Convention on Aesthetic ... 17-19, 2016. Testart will present and discuss new trends in anti-aging stem cell ...
(Date:11/30/2015)... radiology technique shows promise for helping morbidly obese patients lose ... presented today at the annual meeting of the Radiological Society ... --> --> Gastric artery embolization ... way to stop bleeding in emergency situations, but the idea ... is new. Mubin Syed , M.D., interventional radiologist ...
(Date:11/30/2015)... 30, 2015 Harvard Apparatus Regenerative Technology, ... company developing bioengineered organ implants for life-threatening conditions, ... The NASDAQ Stock Market that it has regained ... letter noted that as a result of the ... exceeded $1.00 per share for more than ten ...
(Date:11/30/2015)...  Champions Oncology, Inc. (CSBR), engaged in the development ... development and use of oncology drugs, today announced that ... presenting at the LD MICRO Investor Conference on Wednesday, ... The conference, held at the Luxe Sunset Bel Air ... will feature 200 small/micro-cap companies and is expected to ...
Breaking Biology Technology: